Document is current

Article History

Received: 17 October 2023

Accepted: 16 November 2023

First Online: 15 December 2023

Change Date: 31 January 2024

Change Type: Update

Change Details: The original online version of this article was revised to remove the unnecessary query text from the Abstract section.

Declarations

:

: MAC reports receiving honoraria from BMS, Astellas, Janssen, MSD, Sanofi, Bayer, Roche, Pfizer, Novartis, and Ipsen; consulting or advisory roles from BMS, MSD, Bayer, EUNSA, Pfizer, Roche, Janssen, Pierre Febre, and Ipsen, and travel expenses from Janssen, Astellas, Roche, Ipsen, and MSD. CAF reports consulting or advisory roles for Pfizer, Merck/Pfizer, Bayer, and AstraZeneca; and travel expenses from Roche, Pfizer, Ipsen. RMB reports consulting or advisory and/or speakers bureaus for Sanofi Aventis, AstraZeneca, Merck Sharp & Dohme, Astellas, Pfizer, and BMS; and receiving travel and accommodations expenses from Roche, Sanofi Aventis, Astellas, Janssen, Merck Sharp & Dohme, Bayer, and Pfizer. PM reports receiving honoraria for speaker engagements, advisory roles or continuous medical education from Astellas, Astra Zeneca, Janssen, MSD, Bayer, Pfizer, Ipsen, Roche, BMS, and Merck; travel arrangements from Bayer and Merck; research funding from Roche; and clinical trial payments from Astellas, Astra Zeneca, Janssen, Bayer, Pfizer, Roche, BMS, Merck, Exelixis, and Novartis. ARV reports serving as advisor for Pfizer, BMS, Merck, MSD, Astellas, Janssen, Bayer, Ipsen and Roche; receiving honoraria or travel expenses from Pfizer, MSD, Astellas, Merck, BMS, Janssen, Astra Zeneca, Roche, Bayer, Ipsen and Sanofi Aventis. MJMV reports advisory board, speaker, and/or non-financial support from BMS and Merck; advisory board, speaker from Pfizer; advisory board from EISAI and MSD; speaker from Eusa; speaker or non-financial support from Roche; advisory board and/or non-financial support from AstraZeneca and Ipsen. XGdM reports consulting from Pfizer, BMS, Ipsen, Roche, Lilly, PharmaMar, EusaPharma, GSK, Merck, Eisai, and Deciphera; speakers bureau from Pfizer, Astellas Pharma, and Eisai; research funding from AstraZeneca, and Incyte; and travel expenses from Pfizer and Roche. JP reports honoraria for speaker engagements, advisory roles or continuous medical education from Astellas, Astra Zeneca, Janssen, MSD, Bayer, Pfizer, Eisai, Ipsen, Sanofi, Roche, BMS, Pierre Fabre, and Merck; travel arrangements from Janssen, Merck-Pfizer, BMS, MSD, Astra Zeneca; research funding from Astellas and Pfizer; clinical trial payments from Astellas, Astra Zeneca, Janssen, MSD, Bayer, Pfizer, Sanofi, Roche, BMS, Merck, AVEO, Exelixis, and Novartis; and consultant roles for Astellas, Roche, and Janssen. CGL is an employee of Merck S.L.U., Madrid, Spain, an affiliate of Merck KGaA. JW, AdP, CD, BSC, and MVB are employees of Pfizer. BPV reports honoraria from BMS, Roche, Ipsen, EUSA Pharma, Pfizer, Astellas Pharma, Bayer, and Merck/Pfizer; consulting or advisory roles from BMS, MSD Oncology, Astellas Pharma, AstraZeneca, Novartis, and Bayer; and travel, accommodations and expenses from Merck/Pfizer.

: No ethical approval was required for these exploratory analyses.

: For this type of study, formal consent was not required.